PMID- 31934044
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200117
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 12
IP  - 6
DP  - 2019
TI  - The impact of BCL-2/MYC protein expression and gene abnormality on primary 
      central nervous system diffuse large B-cell lymphoma.
PG  - 2215-2223
AB  - We determined the effects of the BCL-2, C-MYC, and BCL-6 gene aberrations and 
      their protein expressions on the prognosis of primary central nervous system 
      diffuse B-cell lymphoma (PCNS-DLBCL) patients. The pathological and clinical 
      information of 47 immunocompetent patients was reviewed, and the 
      immunohistochemical markers for BCL2, CD10, BCL6, MUM1, and MYC were reevaluated. 
      Genetic abnormalities included increased copy number, translocation, gene 
      amplification, and double aberration and were detected by fluorescence in situ 
      hybridization (FISH). A survival analysis showed that elevated protein levels in 
      the cerebrospinal fluid (CSF), increased the IPI score, and EBV infection 
      adversely affected survival. However, high BCL2 (>/=70%) and positive MYC 
      expressions (>/=40%) showed no significant influence on survival or BCL-2 gene 
      abnormality, and BCL2/MYC double expression and BCL-2/C-MYC double aberrations 
      were associated with adverse outcomes for PCNS-DLBCL patients.
CI  - IJCEP Copyright (c) 2019.
FAU - Yin, Wenjuan
AU  - Yin W
AD  - Department of Pathology, Zhejiang Chinese Medical University Affiliated Zhejiang 
      Cancer Hospital 1# Banshan East Road, Hangzhou, Zhejiang, China.
AD  - The Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang 
      Province Zhejiang, China.
FAU - Xia, Xianghou
AU  - Xia X
AD  - Department of Breast Cancer Surgery, Zhejiang Chinese Medical University 
      Affiliated Zhejiang Cancer Hospital 1# Banshan East Road, Hangzhou, Zhejiang, 
      China.
FAU - Wu, Meijuan
AU  - Wu M
AD  - Department of Pathology, Zhejiang Chinese Medical University Affiliated Zhejiang 
      Cancer Hospital 1# Banshan East Road, Hangzhou, Zhejiang, China.
FAU - Yang, Haiyang
AU  - Yang H
AD  - Department of Lymphoma, Zhejiang Chinese Medical University Affiliated Zhejiang 
      Cancer Hospital 1# Banshan East Road, Hangzhou, Zhejiang, China.
FAU - Zhu, Xiu
AU  - Zhu X
AD  - Department of Pathology, Zhejiang Chinese Medical University Affiliated Zhejiang 
      Cancer Hospital 1# Banshan East Road, Hangzhou, Zhejiang, China.
FAU - Sun, Wenyong
AU  - Sun W
AD  - Department of Pathology, Zhejiang Chinese Medical University Affiliated Zhejiang 
      Cancer Hospital 1# Banshan East Road, Hangzhou, Zhejiang, China.
FAU - Ge, Minghua
AU  - Ge M
AD  - Departmrnt of Head, Neck and Thyroid Surgery, Zhejiang Provincial People's 
      Hospital 158# Santang Road, Hangzhou, Zhejiang, China.
AD  - The Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang 
      Province Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20190601
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC6949630
OTO - NOTNLM
OT  - BCL2
OT  - BCL6
OT  - MYC
OT  - Primary central nervous system diffuse B-cell lymphoma
OT  - gene aberration
OT  - prognosis
COIS- None.
EDAT- 2020/01/15 06:00
MHDA- 2020/01/15 06:01
PMCR- 2019/06/01
CRDT- 2020/01/15 06:00
PHST- 2019/03/20 00:00 [received]
PHST- 2019/04/18 00:00 [accepted]
PHST- 2020/01/15 06:00 [entrez]
PHST- 2020/01/15 06:00 [pubmed]
PHST- 2020/01/15 06:01 [medline]
PHST- 2019/06/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2019 Jun 1;12(6):2215-2223. eCollection 2019.